In addition, lisocabtagene maraleucel (Breyanzi®) also received FDA approval as a CD19 targeted gene therapy for refractory or relapsed diffuse large B cell Lymphoma (DLBCL) in February 2021. Here, CD19 is linked to diffuse large B-cell lymphoma.